Trials / Completed
CompletedNCT05292092
Essential Pro PMCF Study ( rEPIC04E )
Essential Pro Post-Market Clinical Follow-up Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 161 (actual)
- Sponsor
- Fundación EPIC · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.
Detailed description
The objective of this multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study is to confirm and support the clinical safety and performance of the Essential Pro in a NON-SELECTED, Real World population under daily clinical practice when used as intended by the manufacturer to meet EU Medical Device regulation requirements for post-market clinical follow-up.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Essential pro | Patients in whom treatment with (Essential Pro) has been attempted |
Timeline
- Start date
- 2022-09-26
- Primary completion
- 2025-12-29
- Completion
- 2026-01-18
- First posted
- 2022-03-23
- Last updated
- 2026-01-21
Locations
7 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT05292092. Inclusion in this directory is not an endorsement.